Sensebé Luc, Bourin Philippe
Etablissement Français du Sang Centre-Atlantique (EFS-CA), Tours, France.
Transplantation. 2009 May 15;87(9 Suppl):S49-53. doi: 10.1097/TP.0b013e3181a28635.
Mesenchymal stem cells (MSC) are multipotent adult stem cells harboring a wide range of differentiations and non-human leukocyte antigen-restricted immunosuppressive properties that lead to an increasing use of MSC in immunomodulation and in regenerative medicine. To produce MSC, definitive standards are still lacking. Whatever the starting material used (e.g., bone marrow, adipose tissue, or cord blood), numerous parameters including cell plating density, number of passages, and culture medium, play a major role in the culture process and have to be determined. To date, the different production processes have been effective, and based on phenotypic analysis and differentiation potential, a first set of simple controls have been defined. However, controls of the final product should provide precise data on efficacy and safety. The next challenge will be to develop production processes that reach good manufacturing practices goals and to define more accurate control methods of cultivated MSC.
间充质干细胞(MSC)是多能成体干细胞,具有广泛的分化能力和非人类白细胞抗原限制的免疫抑制特性,这使得MSC在免疫调节和再生医学中的应用越来越广泛。目前仍缺乏生产MSC的明确标准。无论使用何种起始材料(如骨髓、脂肪组织或脐带血),包括细胞接种密度、传代次数和培养基在内的众多参数在培养过程中都起着重要作用,必须加以确定。迄今为止,不同的生产工艺都是有效的,并且基于表型分析和分化潜能,已经定义了第一组简单的控制方法。然而,对最终产品的控制应提供有关疗效和安全性的精确数据。下一个挑战将是开发达到良好生产规范目标的生产工艺,并定义更准确的培养MSC的控制方法。